FDA Proposes Striking GLP-1s From the 503B Bulks List (April 30, 2026)

On April 30, 2026, the FDA moved from enforcement discretion to rulemaking: a proposed rule that would formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the inventory of substances outsourcing facilities may compound in bulk without patient-specific prescriptions.

The legal geometry is worth stating plainly. Post-shortage, 503B GLP-1 compounding already lived on borrowed time via enforcement deadlines; the proposed rule would convert that posture into regulation, foreclosing the large-batch lane even if future litigation or shortage claims revived it. What the rule does not touch is the 503A patient-specific pathway — the contested "personalized prescription" theory most current programs use — which is structurally harder to eliminate and remains the industry's operating room.

Read against the year's other moves — the February letters, the additive findings, the brand-only pivots — the direction is one-way: compounded GLP-1 supply is contracting toward smaller, prescription-by-prescription channels while approved-product prices fall. Our standing advice sits in the legal-status guide: monthly terms over prepaid, named pharmacies over silence, and dates on every figure — including ours.